Table 4 Primary efficacy outcomes of subgroup analysis in European patients
Placebo (n = 19) | Eptinezumab 100 mg (n = 16) | |
|---|---|---|
Primary endpoint | ||
Change from baseline in MMDs (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.3 (1.48) | -8.6 (1.73) |
Difference from placebo (95% CI) | -3.3 (-8.0 to 1.5) | |
p-value vs placebo | 0.1713 | |